Sunday, July 28, 2013

[Comment] The promise of innovation in radiation oncology?

[Comment] The promise of innovation in radiation oncology?
The Lancet Oncology

The adjective "existential" is rarely used in radiation oncology. It is defined as "of, relating to, or affirming existence". The word is frequently used in political discourse. If, for example, one is worried about the presence or absence of nuclear weapons on the Korean peninsula or Iran, one might say that these represent "an existential issue for neighbouring countries", to the extent that it bears upon their future existence.

Original Article: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70344-9/fulltext?rss=yes

[Correspondence] Advanced supportive care for patients with cancer in Latin America

[Correspondence] Advanced supportive care for patients with cancer in Latin America
The Lancet Oncology

We read with great interest The Lancet Oncology Commission addressing the increasing burden of cancer in Latin American and Caribbean countries and we congratulate the authors for such an initiative. However, we would like to add our perspective regarding the use of advanced life support and in-hospital resources for patients with cancer. Once the disease is established, the management of patients with cancer is invariably complex and multifaceted, irrespective of the disease stage or phase. The implications of providing the most appropriate current and future anticancer treatment modalities, including palliative care in cases of advanced-stage disease, were discussed well and resulted in a series of recommended actions to improve cancer care.

Original Article: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70269-9/fulltext?rss=yes

[Review] Molecular neuro-oncology in clinical practice: a new horizon

[Review] Molecular neuro-oncology in clinical practice: a new horizon
The Lancet Oncology

Primary brain tumours are heterogeneous in histology, genetics, and outcome. Although WHO's classification of tumours of the CNS has greatly helped to standardise diagnostic criteria worldwide, it does not consider the substantial progress that has been made in the molecular classification of many brain tumours. Recent practice-changing clinical trials have defined a role for routine assessment of MGMT promoter methylation in glioblastomas in elderly people, and 1p and 19q codeletions in anaplastic oligodendroglial tumours.

Original Article: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70168-2/abstract?rss=yes

Friday, July 26, 2013

Neural stem cell sparing by linac based intensity modulated stereotactic radiotherapy in intracranial tumors

Neural stem cell sparing by linac based intensity modulated stereotactic radiotherapy in intracranial tumors
Radiation Oncology

Background: Neurocognitive decline observed after radiotherapy (RT) for brain tumors in long time survivors is attributed to radiation exposure of the hippocampus and the subventricular zone (SVZ). The potential of sparing capabilities for both structures by optimized intensity modulated stereotactic radiotherapy (IMSRT) is investigated. Methods: Brain tumors were irradiated by stereotactic 3D conformal RT or IMSRT using m3 collimator optimized for PTV and for sparing of the conventional OARs (lens, retina, optic nerve, chiasm, cochlea, brain stem and the medulla oblongata). Retrospectively both hippocampi and SVZ were added to the list of OAR and their dose volume histograms were compared to those from two newly generated IMSRT plans using 7 or 14 beamlets (IMSRT-7, IMSRT-14) dedicated for optimized additional sparing of these structures. Conventional OAR constraints were kept constant. Impact of plan complexity and planning target volume (PTV) topography on sparing of both hippocampi and SVZ, conformity index (CI), the homogeneity index (HI) and quality of coverage (QoC) were analyzed. Limits of agreement were used to compare sparing of stem cell niches with either IMSRT-7 or IMSRT-14. The influence of treatment technique related to the topography ratio between PTV and OARs, realized in group A-D, was assessed by a mixed model. Results: In 47 patients CI (p <=0.003) and HI (p < 0.001) improved by IMSRT-7, IMSRT-14, QoC remained stable (p >= 0.50) indicating no compromise in radiotherapy. 90% of normal brain was exposed to a significantly higher dose using IMSRT. IMSRT-7 plans resulted in significantly lower biologically effective doses at all four neural stem cell structures, while contralateral neural stem cells are better spared compared to ipsilateral. A further increase of the number of beamlets (IMSRT-14) did not improve sparing significantly, so IMSRT-7 and IMSRT-14 can be used interchangeable. Patients with tumors contacting neither the subventricular zone nor the cortex benefit most from IMSRT (p < 0.001). Conclusion: The feasibility of neural stem cell niches sparing with sophisticated linac based inverse IMSRT with 7 beamlets in an unselected cohort of intracranial tumors in relation to topographic situation has been demonstrated. Clinical relevance testing neurotoxicity remains to be demonstrated.

Original Article: http://www.ro-journal.com/content/8/1/187

The benefit of whole brain reirradiation in patients with multiple brain metastases

The benefit of whole brain reirradiation in patients with multiple brain metastases
Radiation Oncology - Latest Articles

Background: To assess the outcomes, symptom palliation and survival rates in patients who received repeat whole brain radiotherapy (WBRT). Methods: Twenty-eight patients who had progression of brain metastasis received a second course of WBRT. Univariate log-rank testing and multivariate Cox regression analysis were used to determine the factors for death among several variables (cumulative BED [BEDcumulative], primary tumor site, Karnofsky performance scale [KPS], previous SRS, number of metastases and absence of extracranial metastases). Correlations between variables and treatment response were evaluated with the Chi-squared test. Results: The median KPS was 60 (range 50 to 100) at the initiation of reirradiation. The median time interval between the two courses of WBRT was 9.5 months (range 3--27 months). The median doses of the first course and the second course of WBRT were 30 Gy (range 20 to 30 Gy) and 25 Gy (range 20 to 30 Gy), respectively. The mean BEDcumulative was 129.5 Gy (range 110 to 150 Gy). Severe or unexpected toxicity was not observed. Symptomatic response was detected in 36% of the patients. The median overall survival following reirradiation was 3 months (range 1 to 12 months, 95% CI 1.82-4.118). Survival was significantly better in responders (median 10 months, 95% CI 3.56-16.43) compared with non-responders (median 2 months, 95% CI 1.3-2.64) (p = 0.000). In multivariate analysis, patients that had lung cancer (p = 0.01), initial KPS >=60 (p = 0.03) or longer intervals to reirradiation (p = 0.01) had significantly better survival rates. Conclusions: A careful second course of whole brain irradiation might provide a symptomatic and survival benefit in patients with good performance status and longer cranial progression-free intervals.

Original Article: http://www.ro-journal.com/content/8/1/186

Book: Thoughts from Hospital (Coming Soon! )

Book: Thoughts from Hospital (Coming Soon! )
Neurosurgery Blog

"It is better to go to a house of mourning than to go to a house of feasting, for death is the destiny of everyone; the living should take this to heart." Ecclesiastes 7:2

em breve

The post Book: Thoughts from Hospital (Coming Soon! ) appeared first on NEUROSURGERY BLOG.

Original Article: http://neurocirurgiabr.com/book-thoughts-from-hospital-coming-soon/?utm_source=rss&utm_medium=rss&utm_campaign=book-thoughts-from-hospital-coming-soon

Book: Thoughts from Hospital (Coming Soon! )

Book: Thoughts from Hospital (Coming Soon! )
Neurosurgery Blog

"It is better to go to a house of mourning than to go to a house of feasting, for death is the destiny of everyone; the living should take this to heart." Ecclesiastes 7:2

em breve

The post Book: Thoughts from Hospital (Coming Soon! ) appeared first on NEUROSURGERY BLOG.

Original Article: http://neurocirurgiabr.com/book-thoughts-from-hospital-coming-soon/?utm_source=rss&utm_medium=rss&utm_campaign=book-thoughts-from-hospital-coming-soon

Brain-tumor-associated mutation detected in cerebrospinal fluid using non-invasive digital PCR technology

Brain-tumor-associated mutation detected in cerebrospinal fluid using non-invasive digital PCR technology
Neurology News & Neuroscience News from Medical News Today

Massachusetts General Hospital (MGH) researchers and their colleagues have used digital versions of a standard molecular biology tool to detect a common tumor-associated mutation in the cerebrospinal fluid (CSF) of patients with brain tumors...

Original Article: http://www.medicalnewstoday.com/releases/263839.php

Saturday, July 20, 2013

Missed Diagnoses Trigger Primary Care Malpractice Claims

Missed Diagnoses Trigger Primary Care Malpractice Claims
Medscape Today- Medscape

Most malpractice claims against primary care physicians are a result of missed diagnoses, especially of cancer and myocardial infarction in adults and meningitis in children, as well as medication errors.
Medscape Medical News

Original Article: http://www.medscape.com/viewarticle/808132?src=rss

Thursday, July 18, 2013

Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis

Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis
Cancer

BACKGROUND Bevacizumab received US Food and Drug Administration approval for use in recurrent glioblastoma based on promising radiographic response data, but without clear evidence that it prolongs survival. A population-based analysis was conducted to determine whether bevacizumab approval was associated with improved glioblastoma survival in the United States. METHODS Surveillance, Epidemiology, and End Results (SEER) Program data were used to compare survival of glioblastoma patients who died in 2006, 2008 (both prior to approval of bevacizumab), and 2010 (after approval of bevacizumab). RESULTS The SEER database contained 1715 patients with glioblastoma who died in 2006, 1924 who died in 2008, and 1968 who died in 2010 who met study inclusion criteria. Median survival was 8 months for those who died in 2006, 7 months in 2008, and 9 months in 2010. The difference in survival between 2008 (pre-bevacizumab) and 2010 (post-bevacizumab) was highly significant. This difference is unlikely to be due to improvements in supportive care in this short interval, because there was no significant difference (P = .4440) between patients who died in 2006 versus those who died in 2008. Between 2008 and 2010, a statistically significant improvement in survival was seen in all age groups except those patients aged 18 to 39 years. CONCLUSIONS Patients who died of glioblastoma in 2010 had lived with disease significantly longer than patients who died in 2008. The most likely explanation for this change is the approval and use of bevacizumab for progressive glioblastoma, indicating that at a population level, treatment strategies involving bevacizumab prolong survival.

Original Article: http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002/cncr.28259

Wednesday, July 17, 2013

New Study Finds Strong Pregnancy Outcomes for Survivors of Childhood Cancer

New Study Finds Strong Pregnancy Outcomes for Survivors of Childhood Cancer
BWH News

Although women who survived childhood cancer face an increased risk of infertility, nearly two-thirds of those who tried unsuccessfully to become pregnant for at least a year eventually conceived.

Original Article: http://www.brighamandwomens.org/about_bwh/publicaffairs/news/pressreleases/PressRelease.aspx?PageID=1514

Can the prognosis of individual patients with glioblastoma be predicted using an online calculator?

Can the prognosis of individual patients with glioblastoma be predicted using an online calculator?
Neuro-Oncology - current issue



Original Article: http://neuro-oncology.oxfordjournals.org/cgi/content/short/15/8/1074?rss=1

Tuesday, July 16, 2013

Pulsed Versus Conventional Radiation Therapy in Combination With Temozolomide in a Murine Orthotopic Model of Glioblastoma Multiforme

Pulsed Versus Conventional Radiation Therapy in Combination With Temozolomide in a Murine Orthotopic Model of Glioblastoma Multiforme
International Journal of Radiation Oncology * Biology * Physics

Purpose: To evaluate the efficacy of pulsed low-dose radiation therapy (PLRT) combined with temozolomide (TMZ) as a novel treatment approach for radioresistant glioblastoma multiforme (GBM) in a murine model.Methods and Materials: Orthotopic U87MG hGBM tumors were established in Nu-Foxn1nu mice and imaged weekly using a small-animal micropositron emission tomography (PET)/computed tomography (CT) system. Tumor volume was determined from contrast-enhanced microCT images and tumor metabolic activity (SUVmax) from the F18-FDG microPET scan. Tumors were irradiated 7 to 10 days after implantation with a total dose of 14 Gy in 7 consecutive days. The daily treatment was given as a single continuous 2-Gy dose (RT) or 10 pulses of 0.2 Gy using an interpulse interval of 3 minutes (PLRT). TMZ (10 mg/kg) was given daily by oral gavage 1 hour before RT. Tumor vascularity and normal brain damage were assessed by immunohistochemistry.Results: Radiation therapy with TMZ resulted in a significant 3- to 4-week tumor growth delay compared with controls, with PLRT+TMZ the most effective. PLRT+TMZ resulted in a larger decline in SUVmax than RT+TMZ. Significant differences in survival were evident. Treatment after PLRT+TMZ was associated with increased vascularization compared with RT+TMZ. Significantly fewer degenerating neurons were seen in normal brain after PLRT+TMZ compared with RT+TMZ.Conclusions: PLRT+TMZ produced superior tumor growth delay and less normal brain damage when compared with RT+TMZ. The differential effect of PLRT on vascularization may confirm new treatment avenues for GBM.

Original Article: http://www.redjournal.org/article/PIIS036030161300463X/abstract?rss=yes

HEAVEN: The head anastomosis venture Project outline for the first human head transplantation with spinal linkage (GEMINI)

HEAVEN: The head anastomosis venture Project outline for the first human head transplantation with spinal linkage (GEMINI)
Table of Contents : Surgical Neurology International : 2010 - 1(1)

Sergio Canavero

Surgical Neurology International 2013 4(2):335-342

In 1970, the first cephalosomatic linkage was achieved in the monkey. However, the technology did not exist for reconnecting the spinal cord, and this line of research was no longer pursued. In this paper, an outline for the first total cephalic exchange in man is provided and spinal reconnection is described. The use of fusogens, special membrane-fusion substances, is discussed in view of the first human cord linkage. Several human diseases without cure might benefit from the procedure.

Original Article: http://www.surgicalneurologyint.com/article.asp?issn=2152-7806;year=2013;volume=4;issue=2;spage=335;epage=342;aulast=Canavero

Sphenoid wing en plaque meningiomas: Surgical results and recurrence rates

Sphenoid wing en plaque meningiomas: Surgical results and recurrence rates
Table of Contents : Surgical Neurology International : 2010 - 1(1)

Nuno M Simas, João Paulo Farias

Surgical Neurology International 2013 4(1):86-86

Background: Sphenoid wing en plaque meningiomas are a subgroup of meningiomas defined by its particular sheet-like dural involvement and its disproportionately large bone hyperostosis. En plaque meningiomas represent 2-9% of all meningiomas and they are mainly located in the sphenoid wing. Total surgical resection is difficult and therefore these tumors have high recurrence rates. Methods: Eighteen patients with sphenoid wing en plaque meningiomas surgically treated between January 1998 and December 2008 were included. Clinical, surgical, and follow-up data were retrospectively analyzed. Results: Mean age was 52.2 years and 83% were female. Five patients presented extension of dural component into the orbit and six patients presented cavernous sinus infiltration. Adjuvant radiation therapy was performed in three patients. After a mean follow-up of 4.6 years, five patients developed tumor recurrence - two patients were submitted to surgical treatment and the other three were submitted to radiation therapy. No patient presented recurrence after radiation therapy, whether performed immediately in the postoperative period or performed after recurrence. Patients without tumor extension to cavernous sinus or orbital cavity have the best prognosis treated with surgery alone. When tumor extension involves these locations the recurrence rate is high, especially in cases not submitted to adjuvant radiation therapy. Conclusion: Cavernous sinus and superior orbital fissure involvement are frequent and should be considered surgical limits. Postoperative radiation therapy is indicated in cases with residual tumor in these locations.

Original Article: http://www.surgicalneurologyint.com/article.asp?issn=2152-7806;year=2013;volume=4;issue=1;spage=86;epage=86;aulast=Simas

Sunday, July 14, 2013

Neurosurgery Blog shared an Instagram photo with you

Hi there,

Neurosurgery Blog just shared an Instagram photo with you:


view full image

"What is this? #medicina #medlife #neurosurgeryblog #neurosurgery #neurosurgery #neurology #neurocirurgia #medicine #medstudent"

Thanks,
The Instagram Team

Thursday, July 11, 2013

Endoscopic versus microscopic pituitary surgery

Endoscopic versus microscopic pituitary surgery
Journal of Neurology, Neurosurgery & Psychiatry current issue

In recent years, endoscopic approaches to the pituitary and skull base are being used with increasing frequency for pituitary tumours and other tumours originating in the anterior skull base.

Ammirati and colleagues report the results of their meta-analysis comparing the results of the short-term outcome of pituitary surgery performed using a purely endoscopic approach versus a microscopic approach. They included comparison of mortality, extent of tumour removal and complications (cerebrospinal fluid leak, meningitis, vascular complications, visual complications, diabetes insipidus, hypopituitarism and cranial nerve injury) in their analysis. They conclude that the only significant difference with these two approaches is that the incidence of vascular injury was increased with endoscopic surgery. The types of vascular injury included in the analysis were, in general, potentially serious complications ('Vascular complications included carotid or other vessels injury, intracerebral hematoma, or any symptomatic intratumoural or intrasellar hemorrhage. Venous bleeding from the cavernous...

Original Article: http://jnnp.bmj.com/cgi/content/short/84/8/827?rss=1

Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis

Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis
Journal of Neurology, Neurosurgery & Psychiatry current issue

Endoscopic transsphenoidal pituitary surgery has become increasingly more popular for the removal of pituitary adenomas. It is also widely recognised that transsphenoidal microscopic removal of pituitary adenomas is a well-established procedure with good outcomes. Our objective was to meta-analyse the short-term results of endoscopic and microscopic pituitary adenoma surgery. We undertook a systematic review of the English literature on results of transsphenoidal surgery, both microscopic and endoscopic from 1990 to 2011. Series with less than 10 patients were excluded. Pooled data were analysed using meta-analysis techniques to obtain estimate of death, complication rates and extent of tumour removal. Complications evaluated included cerebrospinal fluid leak, meningitis, vascular complications, visual complications, diabetes insipidus, hypopituitarism and cranial nerve injury. Data were also analysed for tumour size and sex. 38 studies met the inclusion criteria yielding 24 endoscopic and 22 microscopic datasets (eight studies included both endoscopic and microscopic series). Meta-analysis of the available literature showed that the endoscopic transsphenoidal technique was associated with a higher incidence of vascular complications (p<0.0001). No difference was found between the two techniques in all other variables examined. Meta-analysis of the available literature reveals that endoscopic removal of pituitary adenoma, in the short term, does not seem to confer any advantages over the microscopic technique and the incidence of reported vascular complications was higher with endoscopic than with microscopic removal of pituitary adenomas. While we recognise the limitations of meta-analysis, our study suggests that a multicentre, randomised, comparative effectiveness study of the microscopic and endoscopic transsphenoidal techniques may be a reasonable approach towards establishing a true valuation of these techniques.

Original Article: http://jnnp.bmj.com/cgi/content/short/84/8/843?rss=1

How Much Do CT Scans Increase the Risk of Cancer?

How Much Do CT Scans Increase the Risk of Cancer?
Scientific American: Mind and Brain

Ever since physicians started regularly ordering CT (computed tomography) scans four decades ago, researchers have worried that the medical imaging procedure could increase a patient's risk of...

-- Read more on ScientificAmerican.com


Original Article: http://rss.sciam.com/~r/ScientificAmerican-Global/~3/faApFEoh33E/article.cfm

Concurrent Stereotactic Radiosurgery and Bevacizumab in Recurrent Malignant Gliomas: A Prospective Trial

Concurrent Stereotactic Radiosurgery and Bevacizumab in Recurrent Malignant Gliomas: A Prospective Trial
International Journal of Radiation Oncology * Biology * Physics

Purpose: Virtually all patients with malignant glioma (MG) eventually recur. This study evaluates the safety of concurrent stereotactic radiosurgery (SRS) and bevacizumab (BVZ), an antiangiogenic agent, in treatment of recurrent MG.Methods and Materials: Fifteen patients with recurrent MG, treated at initial diagnosis with surgery and adjuvant radiation therapy/temozolomide and then at least 1 salvage chemotherapy regimen, were enrolled in this prospective trial. Lesions <3cm in diameter were treated in a single fraction, whereas those 3 to 5 cm in diameter received 5 5-Gy fractions. BVZ was administered immediately before SRS and 2 weeks later. Neurocognitive testing (Mini-Mental Status Exam, Trail Making Test A/B), Functional Assessment of Cancer Therapy-Brain (FACT-Br) quality-of-life assessment, physical exam, and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) were performed immediately before SRS and 1 week and 2 months following completion of SRS. The primary endpoint was central nervous system (CNS) toxicity. Secondary endpoints included survival, quality of life, microvascular properties as measured by DCE-MRI, steroid usage, and performance status.Results: One grade 3 (severe headache) and 2 grade 2 CNS toxicities were observed. No patients experienced grade 4 to 5 toxicity or intracranial hemorrhage. Neurocognition, quality of life, and Karnofsky performance status did not change significantly with treatment. DCE-MRI results suggest a significant decline in tumor perfusion and permeability 1 week after SRS and further decline by 2 months.Conclusions: Treatment of recurrent MG with concurrent SRS and BVZ was not associated with excessive toxicity in this prospective trial. A randomized trial of concurrent SRS/BVZ versus conventional salvage therapy is needed to establish the efficacy of this approach.

Original Article: http://www.redjournal.org/article/PIIS0360301613004586/abstract?rss=yes

Common Cause For Brain Tumors In Children

Common Cause For Brain Tumors In Children
Neurology News & Neuroscience News from Medical News Today

Brain cancer is the primary cause of cancer mortality in children. Even in cases when the cancer is cured, young patients suffer from the stress of a treatment that can be harmful to the developing brain. In a search for new target structures that would create more gentle treatments, cancer researchers are systematically analyzing all alterations in the genetic material of these tumors...

Original Article: http://www.medicalnewstoday.com/releases/263118.php

Monday, July 8, 2013

8 Recognition Apps Work Almost Like Magic

8 Recognition Apps Work Almost Like Magic
Scientific American: Mind and Brain

In my Scientific American column this month , I noted that in consumer electronics the promises of magic sells. And one of the most important areas for magic simulation these days is recognition....

-- Read more on ScientificAmerican.com


Original Article: http://rss.sciam.com/~r/ScientificAmerican-Global/~3/HMYiDHKxH58/article.cfm

Thursday, July 4, 2013

The prognostic value of tumor necrosis in patients undergoing stereotactic radiosurgery of brain metastases

The prognostic value of tumor necrosis in patients undergoing stereotactic radiosurgery of brain metastases
Radiation Oncology

Background: This retrospective study investigated the outcome of patients with brain metastases after radiosurgery with special emphasis on prognostic impact of visible intratumoral necrosis on survival and local control. Methods: From 1998 through 2008, 149 patients with brain metastases from solid tumors were treated with stereotactic radiotherapy at Luebeck University. Median age was 58.4 years with 11%, 78%, 10% in recursive partitioning analysis (RPA) classes I, II, III, respectively. 70% had 1 metastasis, 29% 2-3 metastases, 2 patients more than 3 metastases, 71% active extracranial disease. Median volume of metastatic lesions was 4.7 cm3, median radiosurgery dose 22 Gy (single fraction). 71% of patients received additional whole-brain irradiation (WBI). All patients were analyzed regarding survival, local, distant failure and prognostic factors, side effects and changes in neurologic symptoms after radiotherapy. The type of contrast-enhancement in MR imaging was also analyzed; metastatic lesions were classified as containing necrosis if they appeared as ring-enhancing with central areas of no or minimal contrast enhancement. Results: Median survival was 7.0 months with 1-year and 5-year survival rates of 33% and 0.4%, respectively. Tumor necrosis (ring-enhancement) was visible on pretreatment MRI scans in 56% of all lesions and lesions with necrosis were larger than non-necrotic lesions (6.7 cm3 vs. 3.2 cm3, p = 0.01). Patients with tumor necrosis had a median survival of 5.4 months, patients without tumor necrosis 7.2 months. Local control rate in the irradiated volume was 70%, median survival without local failure 17.8 months. Control in the brain outside the irradiated volume was 60%, median survival without distant failure 14.0 months. Significant prognostic factors for overall survival were KPS (p = 0.001), presence of tumor necrosis on pretreatment MRI (p = 0.001) with RPA-class and WBI reaching marginal significance (each p = 0.05). Prognostic impact of tumor necrosis remained significant if only smaller tumors with a volume below 3.5 cm3 (p = 0.03). Side effects were rare, only one patient suffered from serious acute side effects. Conclusions: Results of this retrospective study support that stereotactic radiotherapy is an effective treatment option for patients with metastatic brain lesions. The prognostic impact of visible tumor necrosis (ring-enhancement) on pretreatment MRI scans should be further investigated.

Original Article: http://www.ro-journal.com/content/8/1/162

Modern surgical outcomes following surgery for sphenoid wing meningiomas

Modern surgical outcomes following surgery for sphenoid wing meningiomas
Journal of Neurosurgery: Journal of Neurosurgery: Table of Contents

Journal of Neurosurgery, Volume 119, Issue 1, Page 86-93, July 2013.
Object Cushing and Eisenhardt were the first to describe sphenoid wing meningiomas in detail, categorizing globoid tumors into 3 groups: 1) medial; 2) middle; and 3) lateral. The authors review their experience with resection of sphenoid wing meningiomas at a single center, to examine whether this classification predicts clinical presentation and postsurgical outcome. Methods All patients undergoing resection of sphenoid wing meningioma at the authors' institution over a 9-year period were identified. Clinical data were compared from patients with tumors arising at different points along the sphenoid wing to determine if these tumors behaved differently in terms of symptoms, radiographic characteristics, and postsurgical outcome. Results A total of 56 patients underwent microsurgical resection for sphenoid wing meningioma during this period. The rates of optic canal invasion (medial 50% vs middle 5% vs lateral 0%; p < 0.0001, chi-square test), supraclinoid internal carotid artery encasement (medial 32% vs middle 5% vs lateral 0%; p < 0.01, chi-square test), and middle cerebral artery encasement (medial 45% vs middle 24% vs lateral 0%; p < 0.01, chi-square test) were all highest with medial-third tumors. New or worsened neurological deficits occurred in 10 (19%) of 56 patients. Of all the imaging characteristics studied, only location of the tumor along the medial third of the sphenoid wing significantly predicted an increased rate of new or worsened neurological deficit (OR 2.7, p < 0.05). Conclusions The authors report outcomes in a large series of sphenoid wing meningiomas that were treated using modern surgical techniques.

Original Article: http://thejns.org/doi/abs/10.3171/2012.12.JNS11539?ai=ru&mi=0&af=R

Wednesday, July 3, 2013

Intracerebral schwannomas: a rare disease with varying natural history

Intracerebral schwannomas: a rare disease with varying natural history
Journal of Neurosurgery: Journal of Neurosurgery: Pediatrics: Table of Contents

Journal of Neurosurgery: Pediatrics, Volume 12, Issue 1, Page 6-12, July 2013.
Although intracerebral schwannomas are typically regarded as benign intracranial tumors, malignancy and recurrence have been reported among patients harboring such neoplasms. The available literature consists of case reports and small series that present variable characteristics distinguishing these unusual lesions. Little advancement has been made to further the understanding and management of these tumors. The authors present 3 cases from their institution that highlight the difference between typical benign intracerebral schwannomas and histopathological variants that may portend more aggressive behavior. Also provided is a review of the literature in the hope of gaining a better understanding of these rare tumors.

Original Article: http://thejns.org/doi/abs/10.3171/2013.3.PEDS12162?ai=3f6&mi=3ba5z2&af=R

Radiosurgery is still waiting for you to join Twitter...

 
Top corners image
     
 
   
 
 
 

Radiosurgery is still waiting for you to join Twitter...

 
 
  Accept invitation  
 
     
 

Twitter helps you stay connected with what's happening right now and with the people and organizations you care about.

 

Tuesday, July 2, 2013

Vestibular schwannomas in the modern era: epidemiology, treatment trends, and disparities in management

Vestibular schwannomas in the modern era: epidemiology, treatment trends, and disparities in management
Journal of Neurosurgery: Journal of Neurosurgery: Table of Contents

Journal of Neurosurgery, Volume 119, Issue 1, Page 121-130, July 2013.
Object There are a variety of treatment options for the management of vestibular schwannomas (VSs), including microsurgical resection, radiotherapy, and observation. Although the choice of treatment is dependent on various patient factors, physician bias has been shown to significantly affect treatment choice for VS. In this study the authors describe the current epidemiology of VS and treatment trends in the US in the modern era. They also illustrate patient and tumor characteristics and elucidate their effect on tumor management. Methods Patients diagnosed with VS were identified through the Surveillance, Epidemiology, and End Results database, spanning the years 2004–2009. Age-adjusted incidence rates were calculated and adjusted using the 2000 US standard population. The chi-square and Student t-tests were used to evaluate differences between patient and tumor characteristics. Multivariate logistic regression was performed to determine the effects of various patient and tumor characteristics on the choice of tumor treatment. Results A total of 6225 patients with VSs treated between 2004 and 2009 were identified. The overall incidence rate was 1.2 per 100,000 population per year. The median age of patients with VS was 55 years, with the majority of patients being Caucasian (83.16%). Of all patients, 3053 (49.04%) received surgery only, with 1466 (23.55%) receiving radiotherapy alone. Both surgery and radiation were only used in 123 patients (1.98%), with 1504 patients not undergoing any treatment (24.16%). Increasing age correlated with decreased use of surgery (OR 0.95, 95% CI 0.95–0.96; p < 0.0001), whereas increasing tumor size was associated with the increased use of surgery (OR 1.04, 95% CI 1.04–1.05; p < 0.0001). Older age was associated with an increased likelihood of conservative management (OR 1.04, 95% CI 1.04–1.05; p < 0.0001). Racial disparities were also seen, with African American patients being significantly less likely to receive surgical treatment compared with Caucasians (OR 0.50, 95% CI 0.35–0.70; p < 0.0001), despite having larger tumors at diagnosis. Conclusions The incidence of vestibular schwannomas in the US is 1.2 per 100,000 population per year. Although many studies have demonstrated improved outcomes with the use of radiotherapy for small- to medium-sized VSs, surgery is still the most commonly used treatment modality for these tumors. Racial disparities also exist in the treatment of VSs, with African American patients being half as likely to receive surgery and nearly twice as likely to have their VSs managed conservatively despite presenting with larger tumors. Further studies are needed to elucidate the reasons for treatment disparities and investigate the nationwide trend of resection for the treatment of small VSs.

Original Article: http://thejns.org/doi/abs/10.3171/2013.1.JNS121370?ai=ru&mi=0&af=R

Teaching NeuroImages: Diagnostic utility of FDG-PET in neurolymphomatosis

Teaching NeuroImages: Diagnostic utility of FDG-PET in neurolymphomatosis
Neurology recent issues

A 70-year-old woman with a history of non-Hodgkin lymphoma presented with left-sided facial pain. MRI of the face, orbit, and neck was negative (figure). A week later, she developed hypesthesia in a V3 distribution. Repeat MRI was again nondiagnostic but FDG-PET showed increased uptake along the left V3 branch of the trigeminal nerve, as well as in the parotid gland. Biopsy of the left parotid confirmed recurrent lymphoma.

Original Article: http://www.neurology.org/cgi/content/short/81/1/e3?rss=1